Other
Lessee Operating Lease Liability Undiscounted Excess Amount
Neurocrine Biosciences Lessee Operating Lease Liability Undiscounted Excess Amount decreased by 9.4% to $126.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 17.1%, from $152.80M to $126.70M.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ2 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
Changes reflect shifts in the discount rates applied to lease liabilities or changes in the duration of the lease portfolio.
Detailed definition
This represents the difference between the total undiscounted future lease payments and the present value of those payme...
Peer comparison
Comparable across firms with significant real estate or equipment lease portfolios under GAAP.
Metric ID:
other_lessee_operating_lease_liability_undiscounted_exce_ce7a69Historical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.30M | $33.80M | $30.90M | $29.30M | $27.80M | $24.90M | $23.90M | $22.40M | $89.50M | $89.40M | $85.90M | $152.80M | $146.70M | $139.80M | $126.70M |
| QoQ Change | — | -4.2% | -8.6% | -5.2% | -5.1% | -10.4% | -4.0% | -6.3% | +299.6% | -0.1% | -3.9% | +77.9% | -4.0% | -4.7% | -9.4% |
| YoY Change | — | — | — | -17.0% | -17.8% | -19.4% | -18.4% | -19.4% | +259.4% | +274.1% | +283.5% | +70.7% | +64.1% | +62.7% | -17.1% |
Range$22.40M – $152.80M
CAGR+44.1%
Avg YoY Growth+75.5%
Median YoY Growth+22.9%
Current Streak3 quarters decline
Lessee Operating Lease Liability Undiscounted Excess Amount at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's lessee operating lease liability undiscounted excess amount?
- Neurocrine Biosciences (NBIX) reported lessee operating lease liability undiscounted excess amount of $126.70M in Q1 2026.
- How has Neurocrine Biosciences's lessee operating lease liability undiscounted excess amount changed year-over-year?
- Neurocrine Biosciences's lessee operating lease liability undiscounted excess amount decreased by 17.1% year-over-year, from $152.80M to $126.70M.
- What does lessee operating lease liability undiscounted excess amount mean?
- The difference between the total future lease payments and the present value of those payments on the balance sheet.